Health Economics›Chronic lymphocytic leukemia›First-line therapy non-randomized or retrospective data

First-line therapy non-randomized or retrospective data

Chronic lymphocytic leukemia · 15 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Alemtuzumab and Methylprednisolone Variant #01	—	R 549 791	28d	—	—	—	—	—
O-FC Variant #01	—	R 424 251	28d	~28.9 mo	—	~32	~R 13 576 039 PFS proxy · indirect	1
AVO Variant #01	—	R 317 806	28d	—	—	—	—	—
iFCR Variant #01	—	R 134 883	28d	—	—	—	—	—
G-FC Variant #01	—	R 109 781	28d	—	—	—	—	—
CFAR Variant #01	—	R 107 720	28d	—	—	—	—	—
Bendamustine and Obinutuzumab Variant #02	—	R 106 233	28d	—	—	—	—	2
Lenalidomide and Rituximab (R2) Variant #10	—	R 86 746	35d	~39.4 mo	—	~35	~R 3 036 103 PFS proxy · indirect	5
Ruxolitinib monotherapy Variant #01	—	R 60 650	28d	—	—	—	—	2
HDMP-R Variant #03	—	R 54 771	21d	—	—	—	—	—
R-CC Variant #01	—	R 47 657	28d	—	—	—	—	—
PCO N/A - secondary systemic drug	—	R 3 087	21d	—	—	—	—	—
PCR N/A - secondary systemic drug Partial	—	R 172	28d	—	—	—	—	—
Rituximab monotherapy N/A - secondary systemic drug	—	R 52	180d	~53.2 mo	—	~9	~R 468 PFS proxy · indirect	5
Zanubrutinib and Obinutuzumab Partial	—	—	—	—	—	—	—	—

15 of 15 regimens shown